Indegene Limited announced the amalgamation of its two step-down subsidiaries, Indegene Aptilon Services, Inc. and Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC (Canada)). This amalgamation, effective January 01, 2026, has resulted in the formation of a new entity, Indegene Healthcare Canada Inc. Both Indegene Aptilon Services, Inc. and Trilogy Writing & Consulting Inc. are wholly owned by Indegene, Inc. USA, which is itself a wholly owned subsidiary of Indegene Limited. The projected revenue for FY25-26 for Indegene Aptilon Services, Inc. is CAD 1,375,000 (approximately ₹8.5 crore), and for Trilogy Writing & Consulting Inc. is CAD 5,400,000 (approximately ₹33.5 crore). Trilogy's business focuses on medical writing and regulatory documentation services for the pharmaceutical and life-science industries, while Indegene provides digital-first life sciences commercialization services, supporting biopharmaceutical and medical device companies. The rationale for this amalgamation is internal restructuring. The transaction is considered a related party transaction and was conducted at an arm's length basis, with no cash consideration or share exchange involved. There are no anticipated changes in the shareholding pattern of the listed entity as a result of this amalgamation.
